Zimmer Biomet stock trades at USD 88.29 as RBC keeps target

Published on 10/03/2026 at 21:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zimmer Biomet stock carries an RBC Capital USD 110 target after its October 1, 2026 rating update. Q2 revenue reached USD 2.18 billion, up 4.8 percent year over year.

Zimmer Biomet US98956P1021 als farbenfrohe Pop-Art-Comic-Szene mit Chirurg und glänzendem Kniegelenkimplantat im OP-Saal, Illustration mit AI erstellt.

Zimmer Biomet stock (ISIN US98956P1021) was last at USD 88.29 on the NYSE on October 2, 2026, after a USD 0.23 gain, or 0.26 percent, from the prior close of USD 88.06. The immediate investor reference is RBC Capital's Buy rating and USD 110 price target, maintained in a report dated October 1, 2026.

RBC keeps USD 110 target

According to Markets Insider on October 2, 2026, RBC Capital analyst Kendall Au maintained a Buy rating and a USD 110 target after a report released October 1. That target stands 24.6 percent above the USD 88.29 last price, making the analyst view a clear counterpoint to the stock's position 17.4 percent below its USD 106.88 52-week high.

The broader analyst picture is less decisive. MarketBeat lists a consensus Hold rating and an average price target of USD 103.00, based on 22 analysts, while the 52-week low stands at USD 79.12.

Q2 revenue reaches USD 2.18 billion

Zimmer Biomet's latest earnings release, covering the quarter ended June 30, 2026, showed revenue of USD 2.18 billion and net profit of USD 198.3 million, according to Markets Insider. Revenue was USD 2.08 billion in the comparable quarter, while net profit was USD 152.8 million, putting the year-over-year increases at 4.8 percent and 30.0 percent respectively.

The result creates a useful split in the investment case: sales growth remained measured, while profit growth was faster. Zimmer Biomet operates in orthopedic reconstruction, sports medicine, trauma, spine and robotic surgical technologies, so the commercial transformation and product pipeline remain central to how analysts interpret the earnings trend.

Stock stays below yearly high

The market data show a USD 79.12 to USD 106.88 52-week range and a USD 17.1 billion market capitalization as of October 2, 2026. The USD 88.29 last price therefore sits USD 18.59 below the yearly high, while RBC's USD 110 target is USD 3.12 above that high.

For investors, the key tension is visible in the numbers: Q2 revenue grew 4.8 percent, net profit grew 30.0 percent, and the stock remained 17.4 percent below its 52-week high. The next valuation debate centers on whether earnings improvement can narrow that gap.